Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Commentary|Videos|June 4, 2024
Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer
Author(s)Jean-Marc Classe, MD, PhD
Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.
Advertisement
Jean-Marc Classe, MD, PhD, Nantes Université, discusses findings from
Advertisement
Related to this article
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5